neuropharmacologically

share

Examples
neuropharmacologically's examples

  • METHODS: The effects of drugs modulating serotoninergic neurotransmission, the nonselective serotonin receptor antagonist methysergide and the serotonin2 receptor antagonist seganserin were tested neuropharmacologically in thioacetamide-induced acute liver failure in rats. — “Medline ® Abstract for Reference 89 of 'Pathogenesis of”,
  • Cocaethylene: a neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. High concentrations of cocaethylene (EC), the ethyl ester of benzoylecgonine, were measured in the blood of individuals who had concurrently used cocaine and ethanol. — “Cocaethylene: a neuropharmacologically active metabolite”, m.nih.gov
  • rec.drugs.misc general discussion of drugs, emphasis on recreational use. alt.psychoactives: more neuropharmacologically inclined discussion. alt.hemp: cannabis use as food, fuel and fiber (smoking and growing covered by. — “RaveSafe Links to Mailing Lists and Newsgroups”, .za
  • Each group will be comprised of six subjects and will be categorized according to their baseline profile for risk for SDB (< 10 RDI or > 25 RDI) of two, neuropharmacologically distinct, intravenous sedatives. — “Sedation in Patients at Risk for Upper Airway Collapse - Full”, clinicaltrials.gov
  • Cocaethylene: A neuropharmacologically active metabolite assciated with concurrent EC was equipotent to cocaine with respect to inhibition of binding of. — “Scientific Commons: Cocaethylene: A neuropharmacologically”,
  • Dozens of others, which have been designed to address the protein in plaques, the tau protein in tangles, or any of several confirmed or theorized facets of neurodegeneration, are being tested. temporal association cortex1; and neuropharmacologically by such deficits as a decline in cholinergic. — “: Perspectives on CNS Disease Management”,
  • Hepatic transesterification of prodrugs methylphenidate and ethanol Cocaethylene: a neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion". — “Ethylphenidate - Wikipedia, the free encyclopedia”,
  • The online version of Neuropharmacology on ScienceDirect, the world's leading platform for high quality peer-reviewed full-text publications in science, technology and health. Screening Structural-Functional Relationships of Neuropharmacologically Active Organic Compounds at the. — “ScienceDirect - Neuropharmacology, Volume 36, Issue 3, Pages”,
  • Listen to current Borderline Personality Disorder presentations by leading BPD experts The Treatment of BPD with Medications: A Neuropharmacologically-Based Approach. — “Audio Presentations on Borderline Personality Disorder (BPD)”,
  • Neuropharmacologically: the word can be split as follows: Neuro (from the Greek word neuron), which means nerve. Pharmaco (from the Greek word pharmakon), which means drug. Logy (from the Greek word logos), which means knowledge. — “what does neuropharmacologically mean?”,
  • Russell, R (R) :: An immunohistological study of immunoglobulin content of primary central nervous system lymphomas. Cocaethylene: a neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. Oral rehydration. — “Russell, R (R)”, lib.bioinfo.pl
  • The treatment, successful in clinical trials, works by boosting the levels of a chemical messenger in the brain involved in memory and learning for the fact that the patients were neuropharmacologically "dirty", meaning that the patients were already taking other brain-affecting drugs and. — “Alzheimer's drug also combats brain injuries - health - 12”,
  • Conotoxins - new vistas for peptide therapeutics. These highly constrained sulfur rich components or conotoxins represent a unique arsenal of neuropharmacologically active peptides that have been evolutionarily tailored to afford unprecedented and exquisite selectivity for a. — “Conotoxins - new vistas for peptide therapeutics”,
  • A Neuropharmacologically Active Substance from Jellyfish Ganglia. W. J. P. BARNES 1 and G. A. HORRIDGE 1. 1 Gatty Marine Laboratory and Department of Natural History, University of St Andrews. 1. A substance which is extractable with acetone from. — “A Neuropharmacologically Active Substance from Jellyfish”,
  • Peter R. Breggin MD, psychiatrist, author and medical expert provides up to date information on psychiatric drugs, adverse drug effects, and recent criminal, malpractice, and product liability cases. and methylphenidate are "neuropharmacologically alike" (American Psychiatric Association. — “Psychiatric Drug Facts with Dr. Peter Breggin - The hazards”,
  • Schizophrenia Coping · Schizophrenia Research Journal Articles. Another good editorial article - somewhat technical in nature and how this is modulated neuropharmacologically and by experience. — “Schizophrenia Daily News Blog: Understanding the Glass”,
  • Conus peptides represent a unique arsenal of neuropharmacologically active molecules that have been evolutionarily tailored to Conus peptides represent a unique arsenal of neuropharmacologically active molecules that have been evolutionarily tailored to. — “In silico detection of binding mode of J-superfamily”,
  • Short-term memory: a neuropharmacologically distinct process. From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. Printer. — “Short-term memory: a neuropharmacologically distinct process”,
  • neuropharmacologically driven increase in. dopamine is not the sole drugs that produce a dopamine signal neuropharmacologically, dopamine continues to occur at. — “DOI: 10.1126/science.1102384 , 1944 (2004); 306 Science et al”, neuro.uoregon.edu

Videos
related videos for neuropharmacologically

  • Neurotransmitters in tumor angiogenesis and immunity - Sujit Basu, Ohio State University, USA Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines [CANCER] Sujit Basu, The Ohio State University, USA INSUBRIA AUTUMN SCHOOL OF NEUROIMMUNOPHARMACOLOGY From basic science to clinical applications Varese -- Italy, 14th --18th November 2011 DAY THREE -- 16th november 2011 Villa Toeplitz, Via Gian Battista Vico, Varese
  • Neuropharmacological prfile of acacia tortilis growing
  • Rodney Ho Part II - Entrepreneurial Fellows Lecture Part I of University of Washington Pharmaceutics Professor Rodney Ho's lecture titled "High on UW Start-ups: Fueling Innovations in a New Climate of Entrepreneurship." The UW Presidential Entrepreneurial Faculty Fellows lecture series is designed to inspire UW researchers to pursue commercialization of their innovations by showcasing UW Faculty who have succeeded in translating their research into products and therapies, initiated groundbreaking programs for translation, or established model collaborations with industry. Read more at www.uwc4
  • Dr Magill - Discusses Scientifica and the development of the in vivo manipulator (IVM) Scientifica Meets - Dr Peter Magill at the Medical Research Council, Anatomical Neuropharmacology Unit (MRC - based at the University of Oxford). Dr Magill tells Jenni Lacey about how Scientifica helped his research by developing the IVM (in vivo manipulator) to be able to move precisely during his experiments. Dr Magill was involved throughout the process so the Scientifica team could develop the IVM to be ideal for these types of techniques. Find out more about the IVM here: - 3-Axis - Single-Axis
  • Neuroimmunomodulation: a non-reductionist approach - Georges Maestroni, University of Insubria Neural modulation of the immune response - A non-reductionist approach to the physiology of the immune system [BASICS OF NEUROIMMUNOPHARMACOLOGY] Georges JM Maestroni, University of Insubria, Italy and Lab for Experimental Pathology, Locarno (CH) INSUBRIA AUTUMN SCHOOL OF NEUROIMMUNOPHARMACOLOGY From basic science to clinical applications Varese -- Italy, 14th --18th November 2011 DAY TWO -- 15th november 2011 Aula Magna - Facoltà di Scienze MMFFNN - Via JH Dunant n. 3, Varese
  • Building Alien Worlds - Neuropharmacological and Evolutionary Implications of the DMT Flash 1/2 Part 2 - 1st part of a lecture on DMT (N,N-dimethyltryptamine) given by Dr Andrew Gallimore at the joint SSE-SMN conference in Ireland, 2012, explaining how serotonin locks the brain in a consensus-world-building mode and how DMT can rapidly shift the brain into building a bizarre alien reality...
  • (1/3) Dr Magill at MRC on his latest Parkinson's research published in Neuron (Part 1/3) Jenni Lacey met with Dr Magill at the Medical Research Council Anatomical Neuropharmacology Unit (Based at the University of Oxford) to find out about his pioneering work on Parkinson's disease and his recent publication in Neuron. We wanted to learn about the remarkable new cell types his lab has discovered; which break all the rules but could reveal future treatments for Parkinson Disease. Find out more about Dr Magills research and how it research relates to the general public and the impact of his area of Neuroscience: Dr Magill talks about the future of Parkinson's research, potential treatments and surgical intervention: To find out more about Dr Magills research and the Medical Research Council click here:
  • Merton Video #6 : London : The Iain Lee Show on Absolute Radio The Short Description: I was in London, and was a guest on Iain Lee's call-in show on Absolute Radio. I chatted with Iain, and took song and idea requests from his listeners. The Long Description: I was in England for 8 days to film an advert for T-Mobile. On 25th November 2010, I spent the day in Manchester, being filmed in the airport while playing piano and singing about thousands of random strangers as they came through the International Arrivals gate. That night, I flew back to London for Iain's radio show from 11pm to 1am. I didn't have time for dinner, so I quickly pounded a double-espresso and a large glass of wine at a restaurant across the street from the radio station. This video shows some of what happened next. Iain Lee has a regular cast of characters who listen and call in to his radio show. Many of them have perhaps undergone some sort of voluntary neuropharmacological alteration. These people called in to chat with us, to request songs for me to play, and to suggest ideas and stories for my spontaneous lyrics. Iain is a very sharp, very funny guy, and we hit it off immediately. This was one of the funnest evenings I have had in a long time, and was definitely one of the top highlights of my trip to England. Iain's producer, Eloise, keeps all of the technical details running smoothly, and serves as the witty co-host and switchboard operator with callers. The video will look much better if you watch it at 720p resolution. I would ask that you always watch ...
  • SOPICON 2009 , WHO UPPSALA SPECIAL PRIZE FOR My NeuroPharmacology Paper Scientific NeuroPharmacology paper Presentation - Video ***ysis of drug induced gait and motor disturbances in mice and involvement of dopaminergic subsytems in forebrain and demonstration of animal model for Akathisia won WHO UPPSALA special award at SOPICON 2009. Special Thanks to my Professor and my Guide Prof Dr.B.Vasanthi.
  • Zen and The Brain - KFRU interview on James H. Austin lecture at Columbia College, Mo. KFRU 1400 interviews Dr. Anthony Alioto, Professor of History, Schiffman Chair in Ethics, Religious Studies & Philosophy, Humanities about the upcoming Schiffman lecture by Dr. James H. Austin, Neurologist, Researcher and Zen Practitioner. Columbia College, Mo. James H. Austin, MD, is Professor Emeritus of Neurology at the University of Colorado Health Sciences Center. Dr. Austin is a graduate of Harvard Medical School and had his neurology training at Harvard and Columbia. He is the author of Chase, Chance, and Creativity and the author or co-author of more than 130 publications in the fields of neurochemistry, neuropharmacology, and clinical neurology. PRAISE FOR ZEN AND THE BRAIN "In this monumental work, the author marshals the evidence from neuroscience to help clarify which brain mechanisms underlie the subjective states of Zen, and employs Zen to 'illuminate' how the brain 'works' in various states of consciousness. By 'monumental' I refer not merely to the size but to the breadth and depth of coverage of the book." -- George Adelman, Editor of The Encyclopedia of Neuroscience "Austin, by discovering the common roots of Zen and neuroscience, is able to explain the experiential qualities of events and provide testable hypotheses for the experience on philosophical enlightenment. This is a major series of coherent essays of philosophy and neuroscience, reminiscent of the works of Huxley and Churchland, but unique in content and scope." -- Andrew Kertesz, Department ...
  • FEMMES Capstone Event 2010 - Pharmacologists as Sleuths (1) FEMMES Capstone Event - February 27, 2010 Dr. Rochelle D. Schwartz-Bloom "Pharmacologists as Sleuths: Finding Salicylates" The project for FEMMES participants will focus on the role of plants in providing drugs used as medicines. We will discuss the origin of aspirin from the willow tree, and its cousin, salicylate, which is found in numerous plants. Salicylate has been added to a number of household products, including shampoo and chewing gum. The FEMMES participants will perform experiments to determine if certain plants and products contain this drug. They will learn why the drug is found normally in plants and why it is added to products that society uses. They will also learn how it works. As a pharmacologist, Dr. Schwartz-Bloom studies how drugs cure diseases, or cause trouble. Her expertise is in neuropharmacology, or how drugs affect the brain. Dr. Schwartz-Blooms research focuses on how to prevent cell death in the brain with drugs. Her most recent research is in the area of science education, and she has developed several science curricula at the K-12 level. Dr. Schwartz-Bloom is director of RISE at Duke (Raising Interest in Science Education).
  • Adrenergic regulation of dendritic cell functions - Georges Maestroni, University of Insubria Adrenergic regulation of dendritic cell functions - relation to inflammatory skin diseases and cancer vaccines [CANCER] Georges JM Maestroni, University of Insubria, Italy and Lab for Experimental Pathology, Locarno (CH) INSUBRIA AUTUMN SCHOOL OF NEUROIMMUNOPHARMACOLOGY From basic science to clinical applications Varese -- Italy, 14th --18th November 2011 DAY THREE -- 16th november 2011 Villa Toeplitz, Via Gian Battista Vico, Varese
  • Pharmacology & Toxology at The University of Kansas The Department of Pharmacology and Toxicology in the School of Pharmacy at the University of Kansas has research strengths in neuropharmacology especially in neurodegeneration, mood disorders and addiction, and control of energy metabolism and effects of diabetes on the nervous system. We are a dynamic and growing department. The research program is founded on a strong PhD graduate program in Pharmacology & Toxicology.
  • Breakthrough Medicines for Serious Brain Disorders: Jeffrey Conn at TEDxNashville Dr. Conn is the Lee E. Limbird Professor of Pharmacology, and founding Director of the Program in Translational Neuropharmacology and the Vanderbilt Center for Neuroscience Drug Discovery. Conn received the Ph.D. degree in Pharmacology from Vanderbilt University in 1986 and pursued postdoctoral studies in the Department of Pharmacology at Yale University. Dr. Conn joined the Department of Pharmacology at Emory University faculty in 1988 where he rose to the rank of Full Professor and established himself as a leader in studies of neurotransmitter receptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. In 2000, Dr. Conn moved to Merck and Company to assume the position of Senior Director and Head of the Department of Neuroscience at Merck's site in West Point, PA. He moved to Vanderbilt University to start a new program in drug discovery, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. In thespirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized ...
  • My Favorite Things.mpg Recorded in October 2010 at the end of a lecture to medical students on neuropharmacology. Lyrics by Prof. Lloyd Fricker (written in 2001). Thanks to the class of 2013 for help singing the chorus.
  • Youtube's Dirty Little Secret 1 This is THE problem with youtube that they are not trying to fix
  • Roger Pertwee Roger Pertwee, Neuropharmacology & Psychopharmacology Faculty Member and winner of the Wellcome Gold Metal, at the British Pharmacological Society (winter) 2011 meeting, tells Editorial Director Kathleen Wets about his cannabinoid research.
  • Natural Cancer Cure? Tumor Inhibitor? Madrid, Spain: Compounds in marijuana inhibit malignant brain tumor growth in animals, and may provide a potential therapy for human glioma patients, according to a clinical review appearing in the September issue of Neuropharmacology. "Current therapeutic strategies for the treatment of [gliomas] are usually ineffective or just palliative," researchers from the Department of Biochemistry and Molecular Biology at Madrid's Complutense University wrote. "During the last few years, several studies have shown that cannabinoids ... slow the growth of different types of tumours, including gliomas, in laboratory animals. Cannabinoids induce apoptosis (programmed cell death) of glioma cells [in vitro.] In addition, cannabinoid treatment inhibits angiogenesis (growth) of gliomas in vivo. Remarkably, cannabinoids kill glioma cells selectively and can protect non-transformed glial cells from death. These and other findings reviewed here might set the basis for a potential use of cannabinoids in the management of gliomas." Last year, a clinical review in the journal Nature Reviews Cancer made similar recommendations, noting that cannabinoids possess a "favorable drug safety profile" and have shown in clinical trials to inhibit various forms of cancerous tumors, including gliomas, lung carcinoma, breast cancer, skin cancer, thyroid cancer, lymphoma, and prostate cancer. For more information, please contact Paul Armentano, NORML Senior Policy ***yst, at (202) 483-5500. Abstracts of ...
  • Editor-in-Chief Journal of Neurophysiology, David Linden Journal of Neurophysiology. This journal publishes original articles on the function of the nervous system. All levels of function are included, from the membrane and cell to systems and behavior. Experimental approaches include molecular neurobiology, cell culture and slice preparations, membrane physiology, developmental neurobiology, functional neuroanatomy, neurochemistry, neuropharmacology, systems electrophysiology, imaging and mapping techniques, and behavioral ***ysis. Experimental preparations may be invertebrate or vertebrate species, including humans. Theoretical studies are acceptable if they are tied closely to the interpretation of experimental data and elucidate principles of broad interest.
  • 10. Introduction to Neuroscience I (April 21, 2010) Nathan Woodling and Anthony Chung-Ming Ng give a broad overview of the field of neuroscience and how it relates to human biology. They discuss the different lobes of the brain and the cells within as well as neuropharmacology and re-uptake. Stanford University www.stanford.edu Stanford Department of Biology http Stanford University Channel on YouTube
  • Notacon 8 - The Bleeding Edge of Neurohacking This video is part of the Infosec Video Collection at : Notacon 8 - The Bleeding Edge of Neurohacking Synopsis I would like to give a talk on neurohacking and how it can be done very cheap through open source DIY tech. Devices like EEGs, Cranial Electrotherapy Stimulators, rTMS, sound and light machines, and transcranial pulsed ultrasound. Specifically I would like to demonstrate how it is possible to turn a toy into a medical grade EEG sensors using an arduino, and how a Cranial Electrotherapy Stimulator can be made for under in parts. Bio Ed is interested in neuropharmacology, transcranial devices, botany, medical devices, research chemicals. Currently the founder and editor of the Neurohacker Quarterly
  • Pharmacology Ph.D. Graduate Studies Program Pharmacology Graduate Program - Department of Pharmacology - Pharmacology Graduate Programs - Pharmacology PhD Program, Pharmacology PhD Programs, Drug Discovery, Design - neuropharmacology, cardiovascular pharmacology, drug metabolism, toxicology, proteomics, molecular drug metabolism, molecular pharmacology, molecular toxicology, endocrine pharmacology, neuropharmacology, cardiovascular pharmacology, ion channel structure and function, clinical pharmacology, Case Western Reserve University Pharmacology, Graduate, Program, Student, Ph.D., PhD, Doctorate, Ohio, Cleveland
  • Adrenergic mechanisms in vascular inflammation - Franca Marino, University of Insubria Adrenergic mechanisms in vascular inflammation [CARDIOVASCULAR DISEASE] Franca Marino, University of Insubria, Varese, Italy INSUBRIA AUTUMN SCHOOL OF NEUROIMMUNOPHARMACOLOGY From basic science to clinical applications Varese -- Italy, 14th --18th November 2011 DAY THREE -- 16th november 2011 Villa Toeplitz, Via Gian Battista Vico, Varese
  • Neuropharmacology Media Project Clones, Drones, and Cyborgs digital media project. Rethink neuropharmacology.
  • Karen Rommelfanger, Ph.D. - "Magnetic Resonance Imaging (MRI) and Lie Detection" Dr. Karen Rommelfanger is a neuroethicist who works in the Department of Neurology and the Center for Ethics at Emory University. Dr. Rommelfanger received her BS in Chemistry from Angelo State University in Texas; her MS in Neuropharmacology; and her PhD in Neuroscience from Emory University. She was recently selected to be a Fellow in the Department of Neurology as part of the Scholars Program in Interdisciplinary Neuroscience Research, and she is currently the Assistant Director of the Neuroethics Program at the Center for Ethics. Dr. Rommelfanger has been a neuroscience researcher for over 10 years and her work has been published in high-impact peer-reviewed journals such as the Proceedings of the National Academy of Sciences, and the Journal of Neuroscience; her research on Parkinson Disease has been featured in the popular media including Scientific American. She has presented her work at both international and national conferences and has worked in prestigious laboratories in the US and Japan using a broad array of neurotechnologies from brain imaging and behavioral techniques to electrophysiological recording of individual brain cells. Her current research focuses on placebo and Psychogenic Movement Disorders. She is the Neuroscience Editor-in-Residence for the American Journal of Bioethics Neuroscience, the premier journal in neuroethics and regularly speaks in universities and to general audiences about topics at the intersection of neuroscience, ethics, and ...
  • Pharmacology Graduate Program Pharmacology Graduate Program - Department of Pharmacology - Pharmacology Graduate Programs - Pharmacology PhD Program, Pharmacology PhD Programs, Drug Discovery, Design - neuropharmacology, cardiovascular pharmacology, drug metabolism, toxicology, proteomics, molecular drug metabolism, molecular pharmacology, molecular toxicology, endocrine pharmacology, neuropharmacology, cardiovascular pharmacology, ion channel structure and function, clinical pharmacology, Case Western Reserve University Pharmacology, Graduate, Program, Student, Ph.D., PhD, Doctorate, Ohio, Cleveland
  • Presenter: Prof. Ian Robertson at Enterprise Ireland Big Ideas 2011 Engram -- Derisking Neurology and Psychiatry Drug Development Engram Translational Neurosciences offers a unique suite of services for the development of drug treatments for Alzheimer's disease and other neurological conditions. Engram has developed systems that integrate data from behavioural, neuropharmacological and neurophysiological preclinical studies with neuro-cognitive, biomarker and imaging in humans with healthy and illness-impaired mental function. Central Nervous System (CNS) drug research and development is a complex, difficult and expensive process because there is an imperfect relationship between preclinical studies and the human clinical situation. Finding external markers of CNS activity which can be translated from the clinic to the laboratory and vice versa in a meaningful fashion to allow for the assessment of drug effects of brain function has been very difficult. Engram is targeting pharmaceutical and biotechnology companies with R&D programs for treatment of psychiatric and neurological conditions with research capability that has been developed and honed over a period of years with major pharma partners. We have developed rapid, integrative pre-clinical and clinical evaluation methods for novel drug candidates directed at improving mental function that allow the following: • Rapid acceleration of psychiatry and neurology drug development into the clinical pipeline. • Methods that may be useful for stratifying patient populations or identifying ...
  • Pharmacology Graduate Studies Program Pharmacology Graduate Program - Department of Pharmacology - Pharmacology Graduate Programs - Pharmacology PhD Program, Pharmacology PhD Programs, Drug Discovery, Design - neuropharmacology, cardiovascular pharmacology, drug metabolism, toxicology, proteomics, molecular drug metabolism, molecular pharmacology, molecular toxicology, endocrine pharmacology, neuropharmacology, cardiovascular pharmacology, ion channel structure and function, clinical pharmacology, Case Western Reserve University Pharmacology, Graduate, Program, Student, Ph.D., PhD, Doctorate, Ohio, Cleveland
  • Enterprise Ireland 'Big Ideas' - Ian Robertson Engram Engram -- Derisking Neurology and Psychiatry Drug Development Engram Translational Neurosciences offers a unique suite of services for the development of drug treatments for Alzheimer's disease and other neurological conditions. Engram has developed systems that integrate data from behavioural, neuropharmacological and neurophysiological preclinical studies with neuro-cognitive, biomarker and imaging in humans with healthy and illness-impaired mental function. Central Nervous System (CNS) drug research and development is a complex, difficult and expensive process because there is an imperfect relationship between preclinical studies and the human clinical situation. Finding external markers of CNS activity which can be translated from the clinic to the laboratory and vice versa in a meaningful fashion to allow for the assessment of drug effects of brain function has been very difficult. Engram is targeting pharmaceutical and biotechnology companies with R&D programs for treatment of psychiatric and neurological conditions with research capability that has been developed and honed over a period of years with major pharma partners. We have developed rapid, integrative pre-clinical and clinical evaluation methods for novel drug candidates directed at improving mental function that allow the following: • Rapid acceleration of psychiatry and neurology drug development into the clinical pipeline. • Methods that may be useful for stratifying patient populations or identifying ...
  • New therapeutic applications for the control of addiction CEXS Neuropharmacology Laboratory studies the biological substrate of affective disorders and chronic pain in addiction processes, diseases with a great social relevance.
  • Expert of the Month: Masako Isokawa Dr. Masako Isokawa is an associate professor in the Department of Biomedicine in the College of Biomedical Sciences and Health Professions at The University of Texas at Brownsville and Texas Southmost College. She has taught classes in neuroscience, advanced physiology and human anatomy and physiology since 2005. She has received research funding in the past from the National Institute of Health to study cannabinoid mobilization in neurons and caffeine-induced modulation of GABAergic transmission. Isokawa has authored or co-authored papers for the peer-reviewed scientific journals "Neuropharmacology," "Cell Calcium," "Neuroscience" and "Epilepsia." She has presented at the Society for Neuroscience Annual Meeting, the Experimental Biology Annual Meeting, the International Conference on Alzheimer's Disease and the Epilepsy International Congress. She has been invited to lecture at the Kansai Medical School in Osaka, Japan, The University of Texas at San Antonio and the Border Health Seminar Series sponsored by UTB/TSC and The University of Texas Health Science Center at Houston. Isokawa, a native of Japan, has bachelor's, master's and doctoral degrees in neurophysiology from the University of Osaka in Japan. She also has a doctoral degree in psychobiology from Rutgers, The State University of New Jersey. Before coming to UTB/TSC, Isokawa was an assistant professor in the Department of Physiology at The University of Maryland at Baltimore and an instructor in the ...
  • David E. Nichols @ Horizons'08 (1/5) Playlist: Is There a Renaissance in Psychedelic Research and How did it Happen? The definition of renaissance is: a renewal of life, vigor, interest, etc.; rebirth; revival. If there is a renaissance in psychedelic research, to what or to whom can it be attributed? Did it just happen spontaneously? This talk will provide an overview of several events that may have contributed to the genesis of this revival. Incorporation of the Heffter Research Institute in 1993 was one such event, but many individuals played key roles in a process that has taken place over at least three decades and has led us to the present moment. This renaissance, if we can call it that, has resulted from the dedication and work of a relatively few individuals who believed strongly that psychedelics did not get a fair shake in their earlier incarnation in Western society and who have worked to educate the public and to increase understanding of the actual nature of these substances. Biography David E. Nichols, Ph.D. is a Professor of Medicinal Chemistry and Pharmacology in the School of Pharmacy and Pharmaceutical Sciences at Purdue University, as well as a co-founder of the Heffter Institute, where he serves as Director of Preclinical Research. Dr. Nichols has published more than 200 research articles on various aspects of the medicinal chemistry and neuropharmacology His laboratory has published numerous studies elucidating details both of the mechanism of action of MDMA and of the ...
  • Awake Craniotomy
  • Psychedelics in the 21st Century: Breakthroughs in Therapeutics-- Bruce Sewick cod.edu College of DuPage hosted a series of presentations titled, "Psychedelics in the 21st Century," on Saturday, Nov. 3 2012. This event featured top minds in the burgeoning field of psychedelics, and will include recent clinical research on these substances as therapeutic adjuncts to psychotherapy for the treatment of addiction, post-traumatic stress disorder and existential distress at the end of life. Presenters included Nicholas Cozzi, Ph.D., Tom Roberts, Ph.D. and Bruce Sewick, MA, LCPC, CADC. Cozzi is the Director of the Laboratory for Neuropharmacology at the University of Wisconsin-Madison School of Medicine and Public Health. Cozzi's research involves the design, synthesis and mechanistic studies of compounds with central nervous system activity. Compounds of special interest include those of psychedelic, entactogenic and psychostimulant effects; specifically, how these drugs act in the brain to produce changes in consciousness, including spiritual or mystical experiences and changes in mood and cognitions. Roberts began teaching the world's first psychedelics course, Foundations of Psychedelic Studies, at Northern Illinois University in 1981. His publications include the 2-volume Psychedelic Medicine, Spiritual Growth with Entheogens, and Psychedelic Horizons. Roberts is currently working on a third book, The Psychedelic Future of the Mind, which is scheduled for January 2013 publication. Sewick, Clinical Supervisor Crisis/Case Management and Residential ...
  • How the brain processes immune derived signals - Harald Engler, University of Duisburg-Essen Neuroimmune interactions and behavior II: How the brain detects and processes immune derived signals [NEUROPSYCHOPHARMACOLOGY] Harald Engler, University of Duisburg-Essen, Germany INSUBRIA AUTUMN SCHOOL OF NEUROIMMUNOPHARMACOLOGY From basic science to clinical applications Varese -- Italy, 14th --18th November 2011 DAY TWO -- 15th november 2011 Aula Magna - Facoltà di Scienze MMFFNN - Via JH Dunant n. 3, Varese
  • REVISE - The Neuropharmacology Referral Blues A blues riff for acoustic guitar
  • Brain Cancer Vaccine
  • Rodney Ho Part I - Entrepreneurial Fellows Lecture Part I of University of Washington Pharmaceutics Professor Rodney Ho's lecture titled "High on UW Start-ups: Fueling Innovations in a New Climate of Entrepreneurship." The UW Presidential Entrepreneurial Faculty Fellows lecture series is designed to inspire UW researchers to pursue commercialization of their innovations by showcasing UW Faculty who have succeeded in translating their research into products and therapies, initiated groundbreaking programs for translation, or established model collaborations with industry. Read more at www.uwc4
  • Pamela Sklar: 2011 Allen Institute for Brain Science Symposium Pamela Sklar, Mount Sinai School of Medicine "Genomics and psychiatry" Dr. Sklar's major open question focused on how we connect the wealth of information derived from model systems, particularly mice, to advance understanding of human brain diseases. How, she posited, does vast genetic variability translate into particular disease phenotypes? Her approach involves elucidating the molecular genetic markers of diseases such as autism, schizophrenia, and bipolar disease. In a similar vein to Eric Schadt, who spoke at this symposium about integrating biology and genetics via co-expression and neuroimaging networks, Dr. Sklar looks to develop similar strategies for gene expression microarrays, clustering the data to reveal differences between disease and control conditions. A rather novel finding presented here is the concept that deletions in the genome, not just insertions or expansions, can contribute to disease phenotypes. In the path forward on this reductionist approach she aims to construct a variety of images and gene expression interaction networks to identify subnetworks that are driven by human disease variation.
  • Building Alien Worlds - Neuropharmacological and Evolutionary Implications of the DMT Flash 2/2 2nd part of a lecture on DMT (N,N-dimethyltryptamine) given by Dr Andrew Gallimore at the joint SSE-SMN conference in Ireland, 2012, explaining how serotonin locks the brain in a consensus-world-building mode and how DMT can rapidly shift the brain into building a bizarre alien reality... Part 1 -

Blogs & Forum
blogs and forums about neuropharmacologically

  • “Forum. Advanced search. Forum. Board index " Practice Forums " Substance Misuse. Change font size. FAQ. Mephedrone not guilty but next did – that mephedrone was chemically, and neuropharmacologically, an ecstasy-like drug”
    — Support Solutions • View topic - Mephedrone not guilty but,

  • “http:///science/2010/aug/05/mephedrone-not-guilty Mephedrone found not guilty, but the next legal high may be a killer Former Lib Dem MP Evan Harris argues that the rush to make mephedrone illegal – despite a lack of”
    — Mephedrone Not Guilty: Guardian Article,

  • “Psionically advanced cultures refine their arts through many means, much as magically advanced ones research new techniques for manipulating magical psionic power is by altering one's mind neuropharmacologically. A listing of common psychoactive preparations follows. Merdisma”
    — EN World: D&D / RPG News & Reviews - View Single Post,

  • “FCP Poker Forum > Daniel's Forums > Daniel's Poker Blog. Pages: 1, 2, 3. El Guapo. Monday, July 28th, 2008, 11:41 AM. So apparently in 2010 restaurants and other food in CA will no longer be allowed to have trans fats in them, which It is also very different chemically and neuropharmacologically from LSD”
    — FCP Poker Forum > Banning Of Trans Fats In Ca,

  • “Any Breaking News Stories, any New Events or Hot Discussion Items should go in this section. 7 posts • Page 1 Disorders says that cocaine, amphetamines, and methylphenidate (Ritalin) are "neuropharmacologically alike" (page 1221)”
    — • View topic - Rebut this:ADHD Medications Help,

  • “But neuropharmacologically it might work. I think the Naltrexone would only help at There are people on this forum who are taking NAC for its ability to”
    — Preventing or Reducing Tolerance - Must Be A Way - ,

Keywords
related keywords for neuropharmacologically

Similar
similar for neuropharmacologically